(S)-methyl3-((methylsulfonyl)oxy)-2-(tritylamino)propanoate | 76357-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (S)-methyl3-((methylsulfonyl)oxy)-2-(tritylamino)propanoate
• 英文别名: methyl (2S)-3-[(methylsulfonyl)oxy]-2-(tritylamino)propanoate；methyl (2S)-3-methylsulfonyloxy-2-(tritylamino)propanoate
• CAS: 76357-12-5
• 化学式: C₂₄H₂₅NO₅S
• 分子量: 439.532
• InChiKey: ULZIFBTVXNOMFL-QFIPXVFZSA-N

物化性质

• 熔点：
  121-123 °C
• 沸点：
  606.4±55.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-methyl3-((methylsulfonyl)oxy)-2-(tritylamino)propanoate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 以99.5%的产率得到(S)-(-)-1-三苯甲基-2-氮丙啶羧酸甲酯
  参考文献：
  名称：

  从天然的和非天然的正交保护的羊毛硫氨酸的合成Ñ -tritylserine和同种异体-苏氨酸衍生物

  摘要：

  衍生自亲电子的反应性Ñ -tritylserine，苏氨酸和异基因朝向选择的亲核试剂的苏氨酸酯进行了研究。用N-三苯并碘丙氨酸和软亲核试剂（例如硫醇）可获得替代产品的最佳收率。该策略被用于合成胱氨酸的单硫醚类似物羊毛硫氨酸。从L-和d-半胱氨酸，正交保护的加合物硫化物苏- β -甲基-L-半胱氨酸和d青霉胺在81-88％的产率（ee值> 98％）中分离得到。将该策略应用于适当保护用于肽合成的羊毛硫氨酸和环羊毛硫氨酸的制备。

  DOI：

  10.1016/s0957-4166(97)00109-2
• 作为产物：
  描述：

  N-三苯甲基-L-丝氨酸甲酯 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到(S)-methyl3-((methylsulfonyl)oxy)-2-(tritylamino)propanoate
  参考文献：
  名称：

  Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists

  摘要：

  This letter describes the structure-activity relationship (SAR) of the 'right-wing' alpha-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Novel (S)-substituted heteroaryl-bearing alpha-amino acids have been identified as replacements of the 'right-wing' (S)-2,3-diaminopropanoic acid (DAP) moiety. Improvement of potency in the Hut-78 assay in the presence of 10% human serum has also been achieved. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.014

文献信息

• [EN] MODULATORS OF CELLULAR ADHESION<br/>[FR] MODULATEURS DE L'ADHESION CELLULAIRE
  申请人：SUNESIS PHARMACEUTICALS INC

  公开号：WO2005044817A1

  公开（公告）日：2005-05-19

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

  本发明提供具有以下式（I）的化合物及其药学上可接受的衍生物，其中R1-R4、n、p、A、B、D、E、L和AR1如本文中一般描述的那样，并且另外提供这些药物组合物以及用于治疗由CD11/CD18细胞粘附分子家族介导的疾病（例如LFA-1）的使用方法。
• POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：GLINKA TOMASZ

  公开号：US20080318957A1

  公开（公告）日：2008-12-25

  Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.

  揭示了具有多元碱功能的化合物。这些化合物抑制细菌外流泵抑制剂，并与抗菌剂结合使用以治疗或预防细菌感染。这些组合物可以有效对抗通过外流泵机制对抗菌剂产生抗药性的细菌感染。
• [EN] PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS DE PHOSPHONATE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035417A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I''' or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'''或其药物可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备过程。本文所述的抑制剂针对因子D并抑制或调节补体级联。本文所述的因子D抑制剂减少了补体的过度激活。
• Structural Reassignment and Absolute Stereochemistry of Madurastatin C1 (MBJ-0034) and the Related Aziridine Siderophores: Madurastatins A1, B1, and MBJ-0035
  作者：Andrew R. Tyler、Hamed Mosaei、Stephanie Morton、Paul G. Waddell、Corinne Wills、William McFarlane、Joe Gray、Michael Goodfellow、Jeff Errington、Nick Allenby、Nikolay Zenkin、Michael J. Hall

  DOI：10.1021/acs.jnatprod.7b00082

  日期：2017.5.26

  ring. Isolation of madurastatin C1 (1) (also designated MBJ-0034), from Actinomadura sp. DEM31376 (itself isolated from a deep sea sediment), prompted structural reevaluation of the madurastatin siderophores, in line with the recent work of Thorson and Shaaban. NMR spectroscopy in combination with partial synthesis allowed confirmation of the structure of madurastatin C1 (1) as containing an N-terminal

  马杜拉他汀是五肽铁载体，最初被描述为含有不寻常的水杨酸酯封端的N-末端氮丙啶环。从Actinomadura sp。分离madurastatin C1（1）（也称为MBJ-0034）。根据Thorson和Shaaban的最新研究，DEM31376（本身是从深海沉积物中分离出来的）促使对马杜拉他汀铁载体的结构进行了重新评估。核磁共振波谱结合部分合成可以确认马杜拉他汀C1的结构（1）含有N-末端的2-（2-羟苯基）恶唑啉代替最初假定的氮丙啶，而绝对立体化学则通过Harada的先进Marfey方法确定。因此，这项工作进一步支持了Thorson和Shaaban提出的将madurastatin类铁载体（madurastatins A1（2），B1（3），C1（1）和MBJ-0036（4））作为N末端2-（ 2-羟基苯基）恶唑啉。
• Proteomic searches comparing two (R)-lacosamide affinity baits: An electrophilic arylisothiocyanate and a photoactivated arylazide group
  作者：Ki Duk Park、James P. Stables、Rihe Liu、Harold Kohn

  DOI：10.1039/c000987c

  日期：——

  We have advanced a novel strategy to search for lacosamide ((R)-1) targets in the brain proteome where protein binding is expected to be modest. Our approach used lacosamide agents containing “affinity bait” (AB) and “chemical reporter” (CR) units. The affinity bait moiety is designed to irreversibly react with the target, and the CR group permits protein detection and capture. In this study, we report the preparation and evaluation of (R)-N-(4-azido)benzyl 2-acetamido-3-(prop-2-ynyloxy)propionamide ((R)-3) and show that this compound exhibits potent anticonvulsant activities in the MES seizure model in rodents. We compared the utility of (R)-3 with its isostere, (R)-N-(4-isothiocyanato)benzyl 2-acetamido-3-(prop-2-ynyloxy)propionamide ((R)-2), in proteomic studies designed to identify potential (R)-1 targets. We showed that despite the two-fold improved anticonvulsant activity of (R)-3 compared with (R)-2, (R)-2 was superior in revealing potential binding targets in the mouse brain soluble proteome. The difference in these agents’ utility has been attributed to the reactivity of the affinity baits (i.e., (R)-2: aryl isothiocyanate moiety; (R)-3: photoactivated aryl azide intermediates) in the irreversible protein modification step, and we conclude that this factor is a critical determinant of successful target detection where ligand (drug) binding is modest. The utility of (R)-2 and (R)-3 in in situ proteome studies is explored.

  我们提出了一种新颖的策略，在蛋白质结合度较低的大脑蛋白质组中寻找拉科酰胺（(R)-1）靶标。我们的方法使用了含有 "亲和诱饵"（AB）和 "化学报告"（CR）单元的拉科酰胺制剂。亲和诱饵分子被设计成与靶标发生不可逆反应，而 CR 基团则允许蛋白质检测和捕获。在这项研究中，我们报告了 (R)-N-(4-azido)benzyl 2-acetamido-3-(prop-2-ynyloxy)propionamide （(R)-3）的制备和评估，结果表明这种化合物在啮齿动物的 MES 癫痫模型中表现出强效抗惊厥活性。我们比较了(R)-3 和它的同系物(R)-N-(4-异硫氰基)苄基 2-乙酰氨基-3-(丙-2-炔氧基)丙酰胺（(R)-2）在蛋白质组学研究中的作用，这些研究旨在确定潜在的(R)-1 靶点。我们发现，尽管(R)-3 的抗惊厥活性比(R)-2 提高了两倍，但(R)-2 在揭示小鼠大脑可溶性蛋白质组中的潜在结合靶点方面更胜一筹。这些药剂的效用差异归因于亲和饵料（即 (R)-2：芳基异硫氰酸酯分子；(R)-3：光活化芳基叠氮中间体）在不可逆蛋白质修饰步骤中的反应性。我们探讨了 (R)-2 和 (R)-3 在原位蛋白质组研究中的用途。